Compare
Rocket One Inc. vs Silo Pharma, Inc. vs Oncolytics Biotech Inc vs Acurx Pharmaceuticals, Inc.
| Latest fiscal year | Rocket One Inc. RKTO | Silo Pharma, Inc. SILO | Oncolytics Biotech Inc ONCY | Acurx Pharmaceuticals, Inc. ACXP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $72.1K | n/a | n/a |
| Revenue growth (YoY) | n/a | 0.0% | n/a | n/a |
| Gross margin | n/a | 38.6% | n/a | n/a |
| Operating margin | n/a | n/m | n/a | n/a |
| Net margin | n/a | n/m | n/a | n/a |
| Net income | -$12.47M | -$4.23M | -$28.76M | -$7.97M |
| EPS (Diluted) | -$0.90 | -$0.50 | -$0.30 | -$5.32 |
| Operating cash flow | -$9.80M | -$4.66M | -$20.11M | -$6.79M |
| Free cash flow | n/a | n/a | -$20.12M | n/a |
| Cash & equivalents | $6.25M | $4.75M | $5.20M | n/a |
| Total assets | $7.60M | $7.61M | $7.58M | $7.69M |
| Total liabilities | $1.45M | $1.30M | $11.38M | $2.42M |
| Shareholders' equity | $6.15M | $6.31M | -$3.80M | $5.27M |
| Return on year-end equity | -202.7% | -67.0% | n/a | -151.2% |
| Shares outstanding | 15.51M | 13.32M | 108.02M | 2.35M |
Revenue, most recent five fiscal years
| Fiscal year | Rocket One Inc. | Silo Pharma, Inc. | Oncolytics Biotech Inc | Acurx Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | n/a | $72.1K Ended 2025-12-31 | n/a | n/a |
| 1 year earlier | n/a | $72.1K Ended 2024-12-31 | n/a | n/a |
| 2 years earlier | n/a | $72.1K Ended 2023-12-31 | n/a | n/a |
| 3 years earlier | n/a | $72.1K Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | n/a | n/a | n/a | n/a |